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Preterm birth (PTB), defined as birth 
before 37 weeks gestation, is a major 
population health problem. It is the 
number one cause of neonatal morbidity 
and mortality in developed countries--
bearing significant societal healthcare 
costs due to short-term consequences and 
complications.1 It is a source of concern 
for policymakers that PTB accounts for 
12% of all births in the United States, a 
higher rate than other developed nations.2 
PTB preventative strategies include 
transvaginal ultrasound (TVU) screening 
and progesterone administration.3 
Though the exact mechanism of action 
of progesterone is not clear, it is thought 
to provide an anti-inflammatory effect 
and counteract the local decrease in 
progesterone levels to decrease the 
likelihood of PTB.
In 2012, the Society for Maternal-
Fetal Medicine (SMFM) published 
recommendations and the American 
College of Obstetricians and 
Gynecologists (ACOG) published 
an opinion statement relevant to 
progesterone to reduce PTB.4,5 Though a 
number of studies were cited, evidence 
is largely supported by two large trials 
that found vaginal progesterone reduced 
PTB compared to placebo. In 2007, 
Fonseca et al. found that a vaginal 
progesterone suppository (200mg each 
night) reduced spontaneous PTB by 44% 
(19% vs. 34% in the placebo group).6 
The PREGNANT trial (The Effect of 
Vaginal Progesterone Administration 
in the Prevention of Preterm Birth in 
Women With a Short Cervix), a more 
recent randomized multi-center trial, 
demonstrated the efficacy and safety of 
a vaginal progesterone gel (90mg daily) 
in reducing PTB risk and associated 
neonatal complications. Results indicated 
that the vaginal progesterone gel was 
associated with a 45% reduction in 
PTB before 33 weeks (9% treatment vs. 
16% control) and was associated with a 
43% significant reduction in composite 
neonatal morbidity and mortality (8% 
treatment vs. 14% control).7
The evolving evidence regarding 
progesterone has stimulated controversy 
as to whether all pregnant women should 
receive a TVU screening to detect 
short cervix (i.e., universal screening), 
as opposed to screening only women 
determined by their physician to be at 
high risk for PTB. Since high risk is 
typically defined based on history of 
prior PTB, screening only these women 
would leave out two major cohorts of 
the pregnant population: 1) those who 
are pregnant for the first time and have 
a short cervix, and 2) those who have a 
short cervix despite history of full-term 
pregnancies. Proponents of universal 
screening argue that it makes sense to 
support this strategy since evidence 
supports the benefit of progesterone in 
women found to have short cervix.4  On 
the other hand, opponents of universal 
screening contend that: 1) there is a 
lack of efficacy data specifically on the 
strategy of universal TVU screening 
followed by vaginal progesterone; 2) the 
implementation of proper TVU screening 
technique is required in order to ensure 
accurate results; 3) certain geographic 
areas lack sufficient availability of 
TVU screening; 4) in certain women, 
short cervix can be identified without 
TVU; and 5) there is the possibility of 
differing results when TVU screening 
is completed in practice versus within a 
clinical trial.4 SMFM recommendations 
state that, though there is currently 
insufficient evidence to support universal 
screening, it is a reasonable practice for 
individual physicians to choose. 
In summary, while many clinicians 
currently support a strategy of universal 
TVU screening followed by progesterone 
in women detected to have short 
cervix, this remains an acceptable 
but controversial practice. Until more 
evidence is available, the issue will 
persist as a topic of clinical debate.  
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